IGMS vs. SLRN, STTK, TBPH, ANL, FULC, TVTX, TRDA, APLT, KALV, and CDMO
Should you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Acelyrin (SLRN), Shattuck Labs (STTK), Theravance Biopharma (TBPH), Adlai Nortye (ANL), Fulcrum Therapeutics (FULC), Travere Therapeutics (TVTX), Entrada Therapeutics (TRDA), Applied Therapeutics (APLT), KalVista Pharmaceuticals (KALV), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical preparations" industry.
Acelyrin (NASDAQ:SLRN) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.
87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 56.9% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Acelyrin presently has a consensus price target of $23.67, suggesting a potential upside of 458.18%. IGM Biosciences has a consensus price target of $17.44, suggesting a potential upside of 85.58%. Given IGM Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Acelyrin is more favorable than IGM Biosciences.
Acelyrin has a net margin of 0.00% compared to Acelyrin's net margin of -11,568.83%. IGM Biosciences' return on equity of -50.56% beat Acelyrin's return on equity.
In the previous week, IGM Biosciences had 2 more articles in the media than Acelyrin. MarketBeat recorded 2 mentions for IGM Biosciences and 0 mentions for Acelyrin. IGM Biosciences' average media sentiment score of 0.55 beat Acelyrin's score of 0.23 indicating that Acelyrin is being referred to more favorably in the media.
IGM Biosciences received 53 more outperform votes than Acelyrin when rated by MarketBeat users. However, 56.25% of users gave Acelyrin an outperform vote while only 48.82% of users gave IGM Biosciences an outperform vote.
IGM Biosciences has higher revenue and earnings than Acelyrin. IGM Biosciences is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.
Summary
Acelyrin beats IGM Biosciences on 9 of the 15 factors compared between the two stocks.
Get IGM Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IGM Biosciences Competitors List
Related Companies and Tools
